TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07428538: Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Sponsor: Bausch Health Americas, Inc. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 350 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,214,596

Rescue Site Savings

+$2,129,148

Unlock Full NCT07428538 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07428538 Rescue Dossier →